Ohr Pharmaceutical
Ohr Pharmaceutical Inc., a biotechnology company based in New York City, focused on developing novel therapies for serious ocular diseases, particularly targeting wet age-related macular degeneration (wet AMD). Established in 2009, Ohr aimed to create alternatives to invasive treatments, exploring sustained-release drug delivery systems and small molecule drug candidates to improve patient outcomes in ophthalmology.
Despite initial promise, including a Phase IIb trial showing potential vision improvements, Ohr faced challenges with pivotal trial results that did not meet primary endpoints, leading to a strategic review and a subsequent reverse merger with NeuBase Therapeutics in 2019. This transition effectively dissolved Ohr's independent operations, shifting the focus from retinal disease solutions to a preclinical gene editing platform while its historical assets and narrative became part of the new entity.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.